Provided is a clot adhesion preventing agent capable of suppressing adhesion of clot to the inner wall surface of a blood collection container. The clot adhesion preventing agent according to the present invention includes a polyether compound or a silicone oil, and an amino acid.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

Described are medical devices including expandable tubular bodies configured to be implanted into a lumen, wherein the outer surface of the expandable tubular bodies are coupled to a polymer(s).

The invention relates to self-cleaning porous structures, e.g., layers or coatings, fabricated within, applied to, or deposited on a blood contacting surface of a medical device, to prevent activation and aggregation of platelets thereon. In certain embodiments, the layer or coating is composed of multi-layered fibers. The porous structure is applied to or deposited such as to form a permeable wall on the blood contacting surface. The blood travels into the wall and subsequently back out (reversing back into the lumen) during a cardiac cycle. Reversal flow is controlled during the diastole phase such that the backward flow repels the platelets and prevents their activation and aggregation and therefore, minimizes thrombus formation.

Disclosed is an antithrombotic coating composition and a coating method using the same. The composition is highly hydrophilic and biocompatible, thereby enabling a thin and flexible coating layer. The composition is suitably used for coating vascular catheters, stents, guide wires, and other invasive medical devices.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

The present invention relates to substrates and composites having dynamic, reversible micron-level luminal surface deformation including texture or geometric instabilities, e.g., surface wrinkling and folding. The surface deformation and its reversal to the original surface form or to another, different surface form, is effective to reduce or prevent surface fouling and, more particularly, in certain applications, to reduce or prevent unwanted platelet adhesion and thrombus formation. The substrates and composites include a wide variety of designs and, more particularly, biomedical-related designs, such as, synthetic vascular graft or patch designs.

Described herein are nitric oxide releasing materials, methods of making nitric oxide releasing materials, and devices including nitric oxide releasing materials. The nitric oxide releasing material includes a polymer matrix having a plurality of polysiloxanes and nitric oxide-donating crosslinking moieties that covalently crosslink the polysiloxanes. Blood clotting or adhesion of a bio-material to a surface, as well as biofilm formation can be prevented using the methods and materials described.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.